NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc.

$0.14

-0.01 -3.40% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 1:40 PM ET	0.14

Key Stats

Market Cap

247.32M

Avg Volume

3.26M

EPS

-$0.03

52W High

$0.34

52W Low

$0.14

Div. Yield

0.0%

Analyst Ratings

Strong Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-2.07

P/B Ratio

-5.37

P/S Ratio

113.81

EV/EBITDA

-6.90

EV/Revenue

151.13

PEG Ratio

1.72

Margins

Gross Margin 0.0%

Operating Margin (1438.0%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

516.0%

Return on Assets

(59.6%)

Liquidity & Leverage

Current Ratio

0.04

Quick Ratio

0.01

Total Cash

595,000

Total Debt

56.44M

About

Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.